DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Staurosporine is an investigational drug.
There have been 29 clinical trials for Staurosporine. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2017.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, Acute, and Leukemia, Myeloid. The leading clinical trial sponsors are National Cancer Institute (NCI), University Health Network, Toronto, and Memorial Sloan Kettering Cancer Center.
There are two US patents protecting this investigational drug and twenty-one international patents.
Recent Clinical Trials for Staurosporine
|Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome||National Cancer Institute (NCI)||Phase 2/Phase 3|
|Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant||National Cancer Institute (NCI)||Phase 2|
|Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant||Stanford University||Phase 2|
Top disease conditions for Staurosporine
Top clinical trial sponsors for Staurosporine
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Staurosporine||Start Trial||Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus||Seattle Genetics, Inc. (Bothell, WA)||Start Trial|
|Staurosporine||Start Trial||Substituted indole Mcl-1 inhibitors||Vanderbilt University (Nashville, TN)||Start Trial|
|Staurosporine||Start Trial||Tapered looped suture||Covidien LP (Mansfield, MA)||Start Trial|
|Staurosporine||Start Trial||Compositions and methods for inhibiting intimal hyperplasia||Start Trial|
|Staurosporine||Start Trial||Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III||Frequency Therapeutics, Inc. (Woburn, MA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Staurosporine||European Patent Office||1917020||2025-07-07||Start Trial|
|Staurosporine||European Patent Office||2722051||2025-07-07||Start Trial|
|Staurosporine||European Patent Office||3498289||2025-07-07||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|